Theravance Biopharma, Inc. (NASDAQ:TBPH) Sees Significant Growth in Short Interest

Theravance Biopharma, Inc. (NASDAQ:TBPH) was the target of a significant increase in short interest in the month of August. As of August 31st, there was short interest totaling 4,460,000 shares, an increase of 25.3% from the August 15th total of 3,560,000 shares. Currently, 9.6% of the shares of the company are sold short. Based on an average trading volume of 333,700 shares, the short-interest ratio is currently 13.4 days. Based on an average trading volume of 333,700 shares, the short-interest ratio is currently 13.4 days. Currently, 9.6% of the shares of the company are sold short.

Insiders Place Their Bets

In related news, SVP Rhonda Farnum sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $11.39, for a total value of $113,900.00. Following the transaction, the senior vice president owned 326,918 shares in the company, valued at approximately $3,723,596.02. This represents a 2.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 6.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Theravance Biopharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Nuveen LLC bought a new position in Theravance Biopharma in the first quarter worth approximately $3,348,000. Jefferies Financial Group Inc. raised its position in Theravance Biopharma by 1,191.9% in the second quarter. Jefferies Financial Group Inc. now owns 276,887 shares of the biopharmaceutical company’s stock worth $3,054,000 after acquiring an additional 255,455 shares during the period. Acadian Asset Management LLC raised its position in Theravance Biopharma by 121,993.7% in the first quarter. Acadian Asset Management LLC now owns 174,594 shares of the biopharmaceutical company’s stock worth $1,554,000 after acquiring an additional 174,451 shares during the period. Qube Research & Technologies Ltd raised its position in Theravance Biopharma by 80.2% in the second quarter. Qube Research & Technologies Ltd now owns 205,280 shares of the biopharmaceutical company’s stock worth $2,264,000 after acquiring an additional 91,341 shares during the period. Finally, BNP Paribas Financial Markets raised its position in shares of Theravance Biopharma by 30.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 387,472 shares of the biopharmaceutical company’s stock valued at $4,274,000 after purchasing an additional 91,300 shares during the period. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Wall Street Analysts Forecast Growth

TBPH has been the subject of several recent analyst reports. BTIG Research upped their price objective on shares of Theravance Biopharma from $24.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, June 27th. Zacks Research downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 15th. Wall Street Zen raised shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 16th. Jones Trading raised shares of Theravance Biopharma to a “strong-buy” rating and set a $24.00 price target for the company in a research note on Tuesday, June 17th. Finally, B. Riley began coverage on shares of Theravance Biopharma in a research note on Friday, September 12th. They issued a “buy” rating and a $28.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $23.00.

Theravance Biopharma Stock Down 4.1%

NASDAQ:TBPH opened at $13.88 on Friday. The company’s 50 day moving average price is $12.67 and its 200-day moving average price is $10.76. Theravance Biopharma has a 52 week low of $7.88 and a 52 week high of $14.55. The stock has a market cap of $699.00 million, a price-to-earnings ratio of 57.83 and a beta of 0.05.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.